Log In Get Started
Press Releases April 14, 2026 04:15 PM

VALHI ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE

Valhi, Inc. announces expected Q1 2026 earnings release date for May 7, 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
VHI

Valhi, Inc., a diversified company engaged in chemicals, component products, and real estate management, announced that it expects to release its first quarter 2026 earnings after market close on May 7, 2026, pending completion of quarter-end closing procedures.

VALHI ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE
VHI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Valhi operates in multiple sectors: chemicals (TiO2), component products (security and marine components), and real estate development.
  • The company provides a clear earnings release schedule moving forward with expected Q1 2026 results on May 7, 2026.
  • Earnings report timing aligns with typical quarterly disclosures, allowing investors to prepare for updated financial results.

Dallas, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Valhi, Inc. (NYSE:  VHI) announced today that, subject to the completion of quarter-end closing procedures, it expects to report first quarter 2026 earnings in a press release after market close on Thursday, May 7, 2026. 

Valhi, Inc. is engaged in the chemicals (TiO2), component products (security products and recreational marine components) and real estate management and development industries.

* * *

Investor Relations Contact

Bryan A. Hanley
Senior Vice President and Treasurer
Tel. 972-233-1700


Risks

  • Potential risks related to any volatility in the chemical and component product markets which can impact Valhi’s earnings.
  • Uncertainties around the timing and content of the earnings report might affect investor expectations until release.
  • Economic conditions affecting the real estate management and development sectors could influence the company’s overall financial performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026